Evidence map›Paper›PMID 21035160›Full record

ArticleVirology2011

TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection.

Jacob T Minang, Matthew T Trivett, Eugene V Barsov, Gregory Q Del Prete, Charles M Trubey, James A Thomas, Robert J Gorelick, Michael Piatak, David E Ott, Claes Ohlen

Abstract read
In one paragraph

Article in Virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jacob T MinangAIDS and Cancer Virus Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702, USA.
Matthew T Trivett
Eugene V Barsov
Gregory Q Del Prete
Charles M Trubey
James A Thomas
Robert J Gorelick
Michael Piatak
David E Ott
Claes Ohlen
Science Applications International Corporation (United States) · US

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Studies using transformed human cell lines suggest that most SIV strains use CCR5 as co-receptor. Our analysis of primary rhesus macaque CD4(+) T-cell clones revealed marked differences in susceptibility to SIV(mac)239 infection. We investigated whether different levels of CCR5 expression account for clonal differences in SIV(mac)239 susceptibility. Macaque CD4(+) T-cells showed significant CCR5 downregulation 1-2days following CD3 mAb stimulation, which gradually recovered at resting state, 7-10days after activation. Exposure of clones to SIV(mac)239 during their CCR5(low) or CCR5(high) expression states revealed differences in SIV susceptibility independent of surface CCR5 levels. Furthermore, a CCR5 antagonist similarly reduced SIV(mac)239 infection of clones during their CCR5(low) or CCR5(high) expression states. Our data suggest a model where i) very low levels of CCR5 are sufficient for efficient SIV infection, ii) CCR5 levels above this threshold do not enhance infection, and iii) low level infection can occur in the absence of CCR5.

Indexed as

Down-RegulationAnimalsAntibodies, MonoclonalCCR5 Receptor AntagonistsCD3 ComplexCD4-Positive T-LymphocytesCell LineDNA, ViralFemaleGene Products, gagHumansMacaca mulattaMaleReceptors, Antigen, T-CellReceptors, CCR5Simian Acquired Immunodeficiency SyndromeAntibodies, MonoclonalCCR5 Receptor AntagonistsCD3 ComplexDNA, ViralGag protein p27, Simian immunodeficiency virusGene Products, gagReceptors, Antigen, T-CellReceptors, CCR5

Identifiers

PMID21035160
PMCPMC3001627
OpenAlexW2042309401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.